Rapidly climbing sales of the new obesity drug Zepbound and its counterpart for diabetes, Mounjaro, pushed Eli Lilly to a better-than-expected first-quarter profit.
The drugmaker also hiked its sales and earnings forecast for 2024 beyond Wall Street’s expectations even as it hustles to boost manufacturing and catch up to surging demand for the drugs.
Lilly said it was still dealing with supply issues that also hampered the company in the fourth quarter. Company officials expect that to persist through this year, but they emphasized Tuesday that help was on the way.
They expect significant manufacturing increases to occur, starting in the back half of the year.
CEO David Ricks told analysts Tuesday that Lilly was undergoing “the most ambitious expansion plan in our company’s history.”
Indianapolis-based Eli Lilly and Co. recorded $517 million in sales from Zepbound, which received approval from U.S. regulators last November. Total Mounjaro sales more than tripled to $1.81 billion from $568 million in last year’s quarter.
Related articles:
Related suggestion:
Wisconsin GOPTop US and Chinese officials begin talks on AI in GenevaEdmonton Oilers making goalie change. Backup Calvin Pickard will start Game 4 against the CanucksArgentina reports its first singleCanada wildfires: More people are being told to leave area of western Canada as fire growsWhat is the newly passed 'Russia law' that has divided people in Georgia for months?California's wealthiest farming family threatens to reshape small town with new megaAnglo American plans to break up its sprawling business as it tries to fend off takeoverNINETEEN EU countries demand the right to introduce RwandaTennessee governor OKs bill allowing death penalty for child rape convictions
3.6291s , 6497.3046875 kb
Copyright © 2024 Powered by Lilly rides Mounjaro, Zepbound to better ,Earthly Echoes news portal